Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Randomized Controlled Pilot Trial Of Dapagliflozin In Alzheimer's Disease

Authors not listed

Jeff Burns, MD · 2019

Abstract

This is a pilot randomized controlled trial in individuals with probable Alzheimer's disease testing the effects of 10 mg dapagliflozin, taken daily for 12 weeks, on cerebral n-acetyl aspartate (NAA) levels using magnetic resonance spectroscopy (MRS). The investigators will also examine the safety and tolerability of dapagliflozin and explore the effects on systemic NAA levels in blood and urine, cerebral metabolism (fluorodeoxyglucose \[FDG\] PET), systemic metabolic biomarkers that indicate and quantify secondary metabolic effects, and cognitive performance.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2019). Randomized Controlled Pilot Trial Of Dapagliflozin In Alzheimer's Disease. <em>Jeff Burns, MD</em>. https://clinicaltrials.gov/study/NCT03801642
Vancouver
Anonymous. Randomized Controlled Pilot Trial Of Dapagliflozin In Alzheimer's Disease. Jeff Burns, MD. 2019.
BibTeX
@misc{anon2019Random, title = {Randomized Controlled Pilot Trial Of Dapagliflozin In Alzheimer's Disease}, author = {Anonymous}, journal = {Jeff Burns, MD}, year = {2019}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings